At PODS-USA, we leverage our proprietary Precision Oncology & Delivery Systems to target hard-to-treat tumors with surgical accuracy, minimizing toxicity and maximizing efficacy.
The PODS™ Technology
Our multi-functional protein-oriented delivery system represents a leap forward in bio-molecular engineering.
Enhanced ligands ensure our payloads recognize unique tumor micro-environment biomarkers with ultra-high affinity.
Smart encapsulation technology triggers drug release only upon reaching intracellular targets, reducing systemic side effects.
From small molecules to CRISPR-Cas9 proteins, our system adapts to diverse therapeutic modalities.
| Program | Indication | Discovery | Pre-clinical | Phase I | Phase II |
|---|---|---|---|---|---|
| PU-101 | Metastatic Breast Cancer | ||||
| PU-102 | Glioblastoma (GBM) | ||||
| PU-201 | Pancreatic Adenocarcinoma | ||||
| PU-RNA | Solid Tumor Immunotherapy | ||||
* Data represents projected timeline for current Fiscal Year.
We utilize AI-driven structural biology to design ligands that bypass biological barriers like the Blood-Brain Barrier (BBB).
Our proprietary polymers are pH-sensitive and enzyme-responsive, ensuring zero premature release in circulation.
Simultaneous delivery of chemotherapy and gene-silencing agents for multi-pathway tumor inhibition.
Mechanism of Action (MOA)
Intracellular Targeted Release Model
Founded by a consortium of leading oncologists and bio-engineers, PODS-USA is dedicated to bridging the gap between innovative molecular discoveries and bedside patient care. Based in the heart of biotech innovation, we are committed to making "Targeted Therapy" a reality for every patient.
Patents Pending
Sq. Ft Lab Space
Pushing the boundaries of molecular science.
Rigorous clinical standards and transparency.
Designing for quality of life and outcomes.
Accessible solutions for worldwide health.
Connect with our team for investment opportunities, partnerships, or career inquiries.